Fmr LLC Lowers Stake in Encompass Health Co. (NYSE:EHC)

FMR LLC decreased its stake in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 1.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,958,015 shares of the company's stock after selling 28,866 shares during the quarter. FMR LLC owned about 1.94% of Encompass Health worth $189,223,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. UMB Bank n.a. raised its stake in Encompass Health by 387.7% during the third quarter. UMB Bank n.a. now owns 317 shares of the company's stock valued at $31,000 after buying an additional 252 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in shares of Encompass Health by 53.0% in the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company's stock worth $39,000 after purchasing an additional 140 shares in the last quarter. Avior Wealth Management LLC bought a new stake in shares of Encompass Health in the 3rd quarter worth $40,000. Oakworth Capital Inc. bought a new stake in shares of Encompass Health in the 2nd quarter worth $40,000. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in shares of Encompass Health by 58.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company's stock worth $46,000 after purchasing an additional 198 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company's stock.

Encompass Health Trading Up 0.1 %

NYSE EHC traded up $0.08 during trading hours on Tuesday, hitting $102.48. 149,930 shares of the company were exchanged, compared to its average volume of 637,656. The stock has a 50-day moving average price of $98.16 and a 200 day moving average price of $91.45. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. Encompass Health Co. has a 52 week low of $64.15 and a 52 week high of $104.55. The stock has a market cap of $10.32 billion, a PE ratio of 24.73, a price-to-earnings-growth ratio of 1.36 and a beta of 0.86.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings data on Monday, October 28th. The company reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.09. The company had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The firm's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.86 earnings per share. Analysts forecast that Encompass Health Co. will post 4.29 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be paid a $0.17 dividend. The ex-dividend date is Thursday, January 2nd. This represents a $0.68 annualized dividend and a yield of 0.66%. Encompass Health's dividend payout ratio (DPR) is currently 16.43%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on EHC. Truist Financial reissued a "buy" rating and issued a $116.00 target price (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. KeyCorp lifted their price objective on Encompass Health from $115.00 to $117.00 and gave the stock an "overweight" rating in a report on Tuesday, October 29th. Barclays boosted their price target on Encompass Health from $109.00 to $116.00 and gave the company an "overweight" rating in a report on Tuesday, October 29th. Royal Bank of Canada boosted their price objective on Encompass Health from $105.00 to $110.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. Finally, Stephens restated an "overweight" rating and issued a $105.00 price objective on shares of Encompass Health in a research report on Tuesday, August 6th. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Encompass Health currently has a consensus rating of "Buy" and a consensus target price of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.